The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients
Condition(s):Transthyretin Amyloid Polyneuropathy (ATTR-PN)Last Updated:March 12, 2024Completed
Hide Studies Not Open or Pending
Condition(s):Transthyretin Amyloid Polyneuropathy (ATTR-PN)Last Updated:March 12, 2024Completed
Condition(s):Transthyretin Amyloid CardiomyopathyLast Updated:November 9, 2023Completed
Condition(s):Transthyretin (TTR) Amyloid CardiomyopathyLast Updated:January 31, 2024Recruiting
Condition(s):Transthyretin Familial Amyloid PoluneuropathyLast Updated:March 23, 2023Completed
Condition(s):Transthyretin Amyloid CardiomyopathyLast Updated:October 17, 2023Not yet recruiting
Condition(s):Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed PhenotypeLast Updated:August 9, 2023Completed
Condition(s):Transthyretin Familial Amyloid PolyneuropathyLast Updated:September 9, 2015Completed
Condition(s):HealthyLast Updated:March 8, 2021Completed
Condition(s):Healthy VolunteersLast Updated:September 10, 2020Completed
Condition(s):Healthy VolunteersLast Updated:January 7, 2015Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.